Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving symptomatic treatment with pyridostigmine and amifampridine in AChR myasthenia gravis
2021-004110-20Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pyridostigmine and amifampridine in myasthenia gravis (MG) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: MGII change vs placebo. Started Jul 2022; status: completed.
02
Drugs
pyridostigmineamifampridine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2021-004110-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004110-20.